147 related articles for article (PubMed ID: 10763802)
21. Tumor necrosis factor and interleukin 1 induce expression of the glycolipid verotoxin receptor in human endothelial cells. Implications for the pathogenesis of the haemolytic uraemic syndrome.
Van de Kar NC; Monnens LA; Van Hinsbergh VW
Behring Inst Mitt; 1993 Aug; (92):202-9. PubMed ID: 8250811
[TBL] [Abstract][Full Text] [Related]
22. The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit.
Bast DJ; Banerjee L; Clark C; Read RJ; Brunton JL
Mol Microbiol; 1999 Jun; 32(5):953-60. PubMed ID: 10361298
[TBL] [Abstract][Full Text] [Related]
23. Role of verotoxin receptors in pathogenesis.
Lingwood CA
Trends Microbiol; 1996 Apr; 4(4):147-53. PubMed ID: 8728608
[TBL] [Abstract][Full Text] [Related]
24. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis.
Johansson D; Kosovac E; Moharer J; Ljuslinder I; Brännström T; Johansson A; Behnam-Motlagh P
BMC Cancer; 2009 Feb; 9():67. PubMed ID: 19245689
[TBL] [Abstract][Full Text] [Related]
25. Functionally different pools of Shiga toxin receptor, globotriaosyl ceramide, in HeLa cells.
Falguières T; Römer W; Amessou M; Afonso C; Wolf C; Tabet JC; Lamaze C; Johannes L
FEBS J; 2006 Nov; 273(22):5205-18. PubMed ID: 17059464
[TBL] [Abstract][Full Text] [Related]
26. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.
Cooling LL; Walker KE; Gille T; Koerner TA
Infect Immun; 1998 Sep; 66(9):4355-66. PubMed ID: 9712788
[TBL] [Abstract][Full Text] [Related]
27. Localization of verotoxin receptors in nervous system.
Ren J; Utsunomiya I; Taguchi K; Ariga T; Tai T; Ihara Y; Miyatake T
Brain Res; 1999 Apr; 825(1-2):183-8. PubMed ID: 10216186
[TBL] [Abstract][Full Text] [Related]
28. Verotoxin Receptor-Based Pathology and Therapies.
Lingwood C
Front Cell Infect Microbiol; 2020; 10():123. PubMed ID: 32296648
[TBL] [Abstract][Full Text] [Related]
29. Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2.
Waddell T; Head S; Petric M; Cohen A; Lingwood C
Biochem Biophys Res Commun; 1988 Apr; 152(2):674-9. PubMed ID: 3284526
[TBL] [Abstract][Full Text] [Related]
30. Influence of phospholipid chain length on verotoxin/globotriaosyl ceramide binding in model membranes: comparison of a supported bilayer film and liposomes.
Arab S; Lingwood CA
Glycoconj J; 1996 Apr; 13(2):159-66. PubMed ID: 8737240
[TBL] [Abstract][Full Text] [Related]
31. Different binding property of verotoxin-1 and verotoxin-2 against their glycolipid receptor, globotriaosylceramide.
Itoh K; Tezuka T; Inoue K; Tada H; Suzuki T
Tohoku J Exp Med; 2001 Dec; 195(4):237-43. PubMed ID: 11908825
[TBL] [Abstract][Full Text] [Related]
32. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
Khine AA; Lingwood CA
J Cell Physiol; 2000 Jan; 182(1):97-108. PubMed ID: 10567921
[TBL] [Abstract][Full Text] [Related]
33. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker.
Heath-Engel HM; Lingwood CA
Angiogenesis; 2003; 6(2):129-41. PubMed ID: 14739619
[TBL] [Abstract][Full Text] [Related]
34. Two distinct binding sites for globotriaosyl ceramide on verotoxins: identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins.
Nyholm PG; Magnusson G; Zheng Z; Norel R; Binnington-Boyd B; Lingwood CA
Chem Biol; 1996 Apr; 3(4):263-75. PubMed ID: 8807854
[TBL] [Abstract][Full Text] [Related]
35. Endothelial heterogeneity in Shiga toxin receptors and responses.
Obrig TG; Louise CB; Lingwood CA; Boyd B; Barley-Maloney L; Daniel TO
J Biol Chem; 1993 Jul; 268(21):15484-8. PubMed ID: 8340376
[TBL] [Abstract][Full Text] [Related]
36. Modelling of the interaction of verotoxin-1 (VT1) with its glycolipid receptor, globotriaosylceramide (Gb3).
Nyholm PG; Brunton JL; Lingwood CA
Int J Biol Macromol; 1995 Jun; 17(3-4):199-204. PubMed ID: 7577818
[TBL] [Abstract][Full Text] [Related]
37. Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms.
Van Setten PA; van Hinsbergh VW; Van den Heuvel LP; van der Velden TJ; van de Kar NC; Krebbers RJ; Karmali MA; Monnens LA
J Am Soc Nephrol; 1997 Dec; 8(12):1877-88. PubMed ID: 9402090
[TBL] [Abstract][Full Text] [Related]
38. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.
Cohen A; Madrid-Marina V; Estrov Z; Freedman MH; Lingwood CA; Dosch HM
Int Immunol; 1990; 2(1):1-8. PubMed ID: 1965141
[TBL] [Abstract][Full Text] [Related]
39. Generation of receptor-active, globotriaosyl ceramide/cholesterol lipid 'rafts' in vitro : A new assay to define factors affecting glycosphingolipid receptor activity.
Nutikka A; Lingwood C
Glycoconj J; 2004; 20(1):33-8. PubMed ID: 14973368
[TBL] [Abstract][Full Text] [Related]
40. Brefeldin A and filipin distinguish two globotriaosyl ceramide/verotoxin-1 intracellular trafficking pathways involved in Vero cell cytotoxicity.
Khine AA; Tam P; Nutikka A; Lingwood CA
Glycobiology; 2004 Aug; 14(8):701-12. PubMed ID: 15102715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
